FOLIGRAF

Indications

• Infertility due to ovarian dysfunction
• Polycystic ovary syndrome (PCOS)
• Assisted reproductive technologies (ART), including in vitro fertilization (IVF)
• Hormonal imbalances affecting menstrual cycles

Dosage

Children: Refer to BNF for Children for specific dosing guidelines related to pediatric patients.

Adults: For fertility treatments, specific dosages of FSH or LH should be determined based on individual patient assessment and response, following established protocols.

Mechanism of action

Follicle development is regulated by the hypothalamic-pituitary-gonadal (HPG) axis. Gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates the anterior pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH promotes the growth and maturation of ovarian follicles, while LH triggers ovulation and the formation of the corpus luteum. Estrogen produced by the growing follicles further regulates the menstrual cycle and reproductive functions.

Pharmacodynamics

The pharmacodynamics of follicle activity involves hormonal regulation and interaction. FSH and LH stimulate ovarian follicles, leading to estrogen production, which has various effects on the reproductive system, including the thickening of the endometrium and regulation of the menstrual cycle. The hormonal feedback mechanisms play a critical role in ensuring proper follicular development and function.

Pharmacokinetics

As follicle development is a physiological process rather than a drug, pharmacokinetics is not applicable. However, in a clinical context, the administration of gonadotropins (like FSH and LH) for fertility treatments would involve understanding their absorption, distribution, metabolism, and excretion. Generally, these hormones are administered via injection, with their effects being immediate and closely monitored during fertility treatments.

Adverse effects

• Ovarian hyperstimulation syndrome
• Multiple pregnancies
• Headaches
• Nausea
• Vomiting
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of ovarian cysts or other ovarian disorders
• Monitor for signs of ovarian hyperstimulation syndrome
• Consider potential for multiple gestation

Pregnancy

Follicle-stimulating hormone (FSH) is used in assisted reproductive technology but should not be used in pregnancy unless clearly needed.

Breast-feeding

There is limited data on the excretion of FSH in breast milk; caution is advised.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injection solution
• Lyophilized powder for reconstitution

Indications

• Menopausal symptoms (e.g., hot flashes, vaginal dryness)
• Hypogonadism
• Thyroid disorders (e.g., hypothyroidism)
• Adrenal insufficiency
• Growth hormone deficiency
• Polycystic ovary syndrome (PCOS)

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines, as these depend on the type of hormone and the condition being treated.

Adults: Refer to the specific hormone type and formulation for dosing guidance in adults, as dosages may vary significantly based on individual patient needs and specific conditions being treated.

Mechanism of action

Hormones exert their effects through binding to specific receptors on target cells, initiating a cascade of intracellular signaling pathways. This may involve the activation of gene expression, modulation of enzyme activity, or alteration of cell membrane permeability. The specific mechanism varies depending on the type of hormone and its target tissues.

Pharmacodynamics

Hormones have varied effects depending on their class and the target tissues involved. They can influence metabolic pathways, regulate growth and development, and affect mood and cognition. Hormones typically act through either genomic mechanisms, involving changes in gene transcription, or non-genomic pathways, which may involve rapid signaling via second messengers.

Pharmacokinetics

The pharmacokinetics of hormones vary widely based on their chemical structure, route of administration, and formulation. Generally, hormones are absorbed into circulation after administration, with peak plasma concentrations occurring at variable times depending on the specific hormone. They may be metabolized in the liver or other tissues, with elimination typically occurring through renal or biliary excretion. Half-lives can range from minutes to hours, influencing dosing frequency.

Interactions

• antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) + hormone replacement therapy: Unknown (decreases effects)
• bosentan + hormone replacement therapy: Unknown (decreases effects)
• ritonavir + hormone replacement therapy: Unknown (decreases effects)
• modafinil + hormone replacement therapy: Unknown (decreases effects)
• rifamycins + hormone replacement therapy: Unknown (decreases effects)
• St John's Wort + hormone replacement therapy: Unknown (decreases efficacy)
• etoricoxib + hormone replacement therapy: Unknown (increases exposure)

Dosage

Children: Dosage for human-derived biological products in pediatrics should be determined based on specific product guidelines and the clinical context.

Adults: Dosage for human-derived biological products varies widely. Refer to specific product information for appropriate dosing.

Mechanism of action

Human physiology is governed by complex biological systems involving various cellular and molecular pathways. The mechanisms of action for human-derived biological products vary widely depending on the specific context, including immune response, hormonal regulation, and metabolic processes.

Pharmacodynamics

Pharmacodynamics in humans involves the interaction of drugs with biological systems, resulting in therapeutic effects. This includes receptor binding, signal transduction, and physiological responses. The effects are influenced by genetic factors, existing health conditions, and concurrent medications.

Pharmacokinetics

Pharmacokinetics in humans involves the absorption, distribution, metabolism, and excretion (ADME) of substances. Factors such as age, sex, body weight, and organ function can significantly influence these processes. Drug absorption may occur via oral, intravenous, or other routes, while distribution depends on blood flow and tissue permeability. Metabolism typically occurs in the liver, and excretion primarily takes place through the kidneys.

Pregnancy

There is no specific information available; consult local guidelines.

Breast-feeding

There is no specific information available; consult local guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Diabetes mellitus
• Chronic kidney disease-related anemia
• Hemophilia
• Cancer (as targeted therapy)
• Autoimmune diseases (e.g., rheumatoid arthritis)

Dosage

Children: Refer to specific product guidelines for dosing information.

Adults: Refer to specific product guidelines for dosing information.

Mechanism of action

Recombinant drugs function by mimicking the action of naturally occurring proteins in the body. For instance, recombinant insulin binds to insulin receptors on target tissues, facilitating glucose uptake and metabolism. Erythropoietin stimulates erythropoiesis by binding to erythropoietin receptors in the bone marrow, promoting the production of red blood cells.

Pharmacodynamics

The pharmacodynamics of recombinant drugs vary depending on the specific protein or hormone being replaced or supplemented. Generally, they exert their effects at the cellular level by interacting with specific receptors, leading to a cascade of biological responses. The therapeutic effects are usually dose-dependent and can vary based on the patient's biological response and the presence of antibodies against the recombinant product.

Pharmacokinetics

Pharmacokinetics of recombinant drugs include absorption, distribution, metabolism, and excretion (ADME) characteristics that can differ significantly based on the specific drug. Many recombinant proteins have a short half-life and require parenteral administration. They are typically distributed throughout the body via the bloodstream, metabolized by the liver and other tissues, and excreted primarily through the kidneys. The pharmacokinetics may be influenced by the patient's age, weight, and overall health.

Pregnancy

Recombinant proteins should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when administering recombinant proteins during breastfeeding, as the effects on the infant are not well established.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze, and protect from light.

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy
• Obesity (as part of a comprehensive weight management program)
• Treatment-resistant depression
• Cognitive enhancement in certain disorders

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on age and weight.

Adults: Refer to the specific BNF for individual stimulant medications for appropriate dosing guidelines.

Mechanism of action

Stimulants enhance the release of neurotransmitters such as dopamine and norepinephrine in the brain. They inhibit the reuptake of these neurotransmitters, leading to increased synaptic concentrations and prolonged effects. This mechanism is particularly relevant in the treatment of ADHD, where increased dopamine activity in the prefrontal cortex can improve attention and behavior regulation.

Pharmacodynamics

Stimulants generally exert their effects by increasing neurotransmitter availability in the synaptic cleft, leading to enhanced neuronal firing rates. This results in improved cognitive function, mood elevation, and increased physical activity. The specific pharmacodynamic profile can vary between different stimulant medications, with some exhibiting a more pronounced effect on dopamine versus norepinephrine pathways.

Pharmacokinetics

Stimulants are typically well absorbed in the gastrointestinal tract and may have varying half-lives depending on the formulation (immediate vs extended release). They are metabolized primarily in the liver, and their elimination is often through the kidneys. The onset of action can range from minutes to hours, with effects lasting from a few hours to over 12 hours in some extended-release forms.

Pregnancy

The use of stimulating agents during pregnancy should be approached with caution due to potential risks to fetal development. It is essential to weigh the benefits against possible adverse effects.

Breast-feeding

Caution is advised when using stimulating agents while breastfeeding, as they may pass into breast milk and affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the container is tightly closed to maintain stability.